Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for September

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 14,819 shares, a drop of 58.5% from the September 15th total of 35,733 shares. Based on an average daily trading volume, of 259,644 shares, the days-to-cover ratio is currently 0.1 days. Currently, 11.4% of the shares of the company are short sold.

Clearmind Medicine Stock Performance

Shares of NASDAQ CMND traded down $0.01 during mid-day trading on Tuesday, hitting $6.54. 7,187 shares of the company were exchanged, compared to its average volume of 117,562. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $10.23 and a 200-day simple moving average of $28.62. Clearmind Medicine has a 1-year low of $5.25 and a 1-year high of $3,840.00. The firm has a market cap of $3.31 million, a price-to-earnings ratio of -0.16 and a beta of 0.93.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Thursday, September 10th. The company reported ($4.56) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Wall Street Zen raised Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.

About Clearmind Medicine

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors.

Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns.

Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly.